Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes Aging & Longevity

The Truth About Full-Body MRIs: A $2,500 Investment in Your Health?

by Team Lumida
May 17, 2024
in Aging & Longevity, Health and Longevity, Lifestyle
Reading Time: 3 mins read
A A
0
man during magnetic resonance imaging

Photo by Charlss GonzHu on Pexels.com

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

  1. Full-body MRI scans, costing $2,500, are gaining popularity among celebrities.
  2. These scans promise early disease detection but come with potential downsides.
  3. Investors eyeing the preventive healthcare market should watch for growth in services like Prenuvo.

What Happened?

Prenuvo, a company specializing in full-body MRI scans, is drawing attention with its preventive approach to health. Charging $2,500 for a comprehensive scan, Prenuvo aims to detect early signs of disease without using ionizing radiation or contrast dyes.

Founded in 2018 in Vancouver, Prenuvo expanded to New York City in April 2023, fueled by $70 million in series A funding. High-profile investors like 23andMe cofounder Anne Wojcicki and actress Cindy Crawford back the company. Demand is soaring, with new clinics opening across North America. The scans can detect tumors, aneurysms, and hundreds of other conditions.

Why It Matters?

Why should you care about Prenuvo’s MRI scans? The trend toward preventive healthcare is growing, driven by a desire to catch diseases early and maintain better health. Prenuvo’s success reflects this shift, suggesting significant market potential. Investors should note that this service, though costly, appeals to health-conscious individuals and those with high cancer risk in their families.

The company’s expansion indicates strong demand and potential for further growth. However, some medical experts caution against over-reliance on such scans, highlighting the psychological stress and potential for unnecessary follow-ups.

What’s Next?

What does the future hold for Prenuvo and similar preventive health services? Prenuvo aims to make its scans a routine part of health check-ups, similar to dental visits or physicals. The company plans to work with employers to offer scans as a benefit, potentially increasing accessibility.

For investors, this represents a growing niche in the healthcare market with substantial room for expansion. As the debate over the efficacy and necessity of full-body MRIs continues, Prenuvo’s focus on preventive care could shape future healthcare trends. Watch for further developments and potential collaborations that may influence the company’s market presence and profitability.

Previous Post

Why Investors Are Going Crazy for Copper: The $43 Billion Battle

Next Post

Inside Equinox’s Elite $40,000 Longevity Program: What You Need to Know

Recommended For You

Novo Nordisk Squeezes Suppliers for Discounts as Eli Lilly Eats Its Lunch in the Obesity Drug Market

by Team Lumida
1 week ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk has written to suppliers seeking price discounts to protect its cost base as it fights to claw back market share lost to Eli Lilly in the...

Read more

Medicare Launches $50/Month Weight-Loss Drug Coverage Today — With Caveats

by Team Lumida
1 week ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

Medicare's "Bridge" program kicks off July 1, offering Wegovy and Zepbound to 12.5–20 million eligible seniors at a $50 monthly copay — down from up to $450 cash...

Read more

FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

by Team Lumida
3 weeks ago
FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

The FDA agreed to reverse its rejection of Regenxbio's Navsunli gene therapy for Hunter syndrome — the third rare-disease drug reversal under new FDA leadership, marking a retreat...

Read more

Nvidia Partners With Abridge to Build an AI Model Trained on Real Doctor-Patient Conversations

by Team Lumida
4 weeks ago
Nvidia’s AI Demand Surge: Hon Hai Ramps Up Server Production

Nvidia and AI medical note-taking startup Abridge are jointly developing a clinical AI model trained on de-identified doctor-patient conversations, using Nvidia's open Nemotron models as a base —...

Read more

Nearly 90% of Americans Have It and Don’t Know It: First Guidelines Issued for CKM Syndrome

by Team Lumida
1 month ago
people holding us a flag during daytime

The American Heart Association and three major medical societies published the first clinical guidelines for cardiovascular-kidney-metabolic syndrome — a cluster of interconnected conditions tied to excess body fat...

Read more

The ‘Trump Slump’ Is Drowning Out No-Tax-on-Tips in Nevada — And Republicans Are Worried

by Team Lumida
1 month ago
man in white button up shirt holding black and white box

Las Vegas tourism dropped 7.5% last year — its sharpest non-pandemic decline since 1970 — and $6 gas is erasing tip tax refunds, as Nevada's Tuesday primary tests...

Read more

Employers Are Slashing GLP-1 Coverage as Costs Spiral — And Some Are Adding Weigh-Ins to Keep It

by Team Lumida
1 month ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

More than a quarter of large companies are adding new criteria for GLP-1 weight-loss coverage while 11% are dropping it altogether, as drug costs balloon and employers struggle...

Read more

The $48 Billion ETF Tax Loophole: How ‘Heartbeat Trades’ Funnel Savings Almost Exclusively to the Wealthy

by Team Lumida
1 month ago
a person sitting at a desk with a calculator and a notebook

A Bloomberg investigation finds that an obscure ETF tax loophole costs the U.S. Treasury $48 billion a year, with the top 1% of earners capturing 40% of the...

Read more

GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

by Team Lumida
1 month ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

Shoppers on weight-loss drugs are dropping a clothing size every month, flooding retailers with returns — one online suit seller saw a 50% jump — and forcing the...

Read more

Weight-Loss Drugs Like Ozempic May Also Slow Cancer — Four New Studies Show Striking Results

by Team Lumida
2 months ago
Eli Lilly and Novo Nordisk Shares Plunge Amid Ozempic Vision Loss Fears

GLP-1 drugs used for diabetes and obesity are linked to reduced tumor progression, lower cancer mortality, and decreased breast cancer risk across hundreds of thousands of patients in...

Read more
Next Post
woman wearing black sports bra

Inside Equinox’s Elite $40,000 Longevity Program: What You Need to Know

Solar Charging Station in the Parking Lot

Xpeng Charges Into Hong Kong with New EV Models

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Fed Signals Rate Cut: What It Means for Your Investments

Fed Signals Rate Cut: What It Means for Your Investments

July 28, 2024

Insulet Corporation Earnings Highlights: Strong Q2 Performance Fueled by Omnipod 5 Demand

August 10, 2024
Apple Invests $500 Million in U.S. Rare-Earth Magnets to Diversify Supply Chain Amid Tariff Pressure

Apple Invests $500 Million in U.S. Rare-Earth Magnets to Diversify Supply Chain Amid Tariff Pressure

July 16, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018